- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01788332
Parp Inhibitor in Advanced Non-Small Cell Lung Cancer (PIN) (PIN)
A Randomised Phase II Trial of Olaparib Maintenance Versus Placebo Monotherapy in Patients With Chemosensitive Advanced Non-Small Cell Lung Cancer
In 2010, more than 35,000 people died in the United Kingdom from lung cancer, the majority from non-small cell cancer (NSCLC). Chemotherapy is one of the main treatments for patients with NSCLC but those treated will still only live for an average of 9 or 10 months after diagnosis.
The purpose of this clinical trial is to find out whether or not giving a drug called Olaparib following chemotherapy will benefit patients with NSCLC who have responded to initial chemotherapy treatment by prolonging the time before the tumour regrows. Olaparib is a new, oral drug developed by AstraZeneca which may help to slow down cancer growth. The rationale for this clinical trial is that chemotherapy damages tumour cell DNA and NSCLC tumours that respond to chemotherapy are less able to repair this damage. This can be exploited by using Olaparib as it blocks an enzyme called Poly (ADP-ribose) polymerase (PARP) which is essential for DNA repair. This will prevent DNA repair and cause cancer cell death by a mechanism known as synthetic lethality. Synthetic lethality arises when a combination of mutation in two or more genes leads to cell death.
Up to 300 patients who are to receive standard chemotherapy treatment will be initially registered into the trial. Of these patients, 114 patients who have responded to chemotherapy will be randomly allocated to receive either Olaparib or an inactive dummy pill or placebo by mouth. The trial will assess whether Olaparib delays disease progression following standard chemotherapy treatment in patients. It will also show whether the side effects of adding Olaparib following standard treatment are acceptable.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a multicentre randomised phase II trial. Patients are initially registered either before or during induction chemotherapy, their response to which will be used to determine whether they are eligible for randomisation. All patients will be asked to consent to archival tissue collection for translational analysis and to provide a translational blood sample. The second consent will precede randomisation to one of two groups of maintenance therapy (olaparib or placebo) with 1:1 randomisation if they have had an objectively measured complete or partial response following standard chemotherapy.
Randomised patients will receive olaparib or placebo until disease progression. They will be monitored by CT scan every two cycles until disease progression, where they will be managed according to local practice. Follow up will be for a maximum of 12 months from the point of randomisation or until disease progression.
All randomised patients for whom we have a baseline translational blood sample will be asked to provide a follow up blood sample upon randomisation and again at radiological progression. Registered patients with progressive disease after the initial induction chemotherapy will be asked to provide a follow-up blood sample at the end of induction chemotherapy.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Blackpool, United Kingdom
- Blackpool Victoria Hospital
-
Bradford, United Kingdom
- Bradford Royal Infirmary
-
Burton Upon Trent, United Kingdom
- Queen's Hospital
-
Cardiff, United Kingdom
- Velindre Cancer Centre
-
Coventry, United Kingdom
- University Hospitals Coventry and Warwickshire NHS Trust
-
Derby, United Kingdom
- Derby Teaching Hospitals NHS Foundation Trust
-
Glasgow, United Kingdom
- Beatson West of Scotland Cancer Centre
-
Haverfordwest, United Kingdom
- Withybush General Hospital
-
Huddersfield, United Kingdom
- Huddersfield Royal Infirmary
-
Lancashire, United Kingdom
- University Hospitals of Morecambe Bay
-
Leeds, United Kingdom
- St James University Hospital
-
Leicester, United Kingdom
- Leicester Royal Infirmary
-
London, United Kingdom
- Charing Cross Hospital
-
Manchester, United Kingdom
- The Christie Nhs Foundation Trust
-
Middlesbrough, United Kingdom
- The James Cook University Hospital
-
Preston, United Kingdom
- Royal Preston Hospital
-
Sheffield, United Kingdom
- Weston Park Hospital
-
Stoke-on-Trent, United Kingdom
- University Hospitals of North Midlands
-
Swansea, United Kingdom
- Singleton Hospital
-
Wrexham, United Kingdom
- Wrexham Maelor Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria - Registration (Stage 1):
- Histological diagnosis of NSCLC. Histology can be either squamous or non-squamous.
- Stage IIIB or stage IV lung cancer that is not amenable to curative therapy.
- Have had no prior systemic chemotherapy for advanced NSCLC. Previous adjuvant or neoadjuvant chemotherapy for non-advanced disease is acceptable. Prior treatment with an oral targeted therapy for e.g. EGFR/ALK or other driver- oncogene mutated lung cancer is allowed. Immunotherapy e.g. with a PD1 or PDL1 targeted agent is allowed.
- Patients who have already started their induction chemotherapy are not eligible for stage 1 of the trial
- Eligible to receive standard platinum doublet-based chemotherapy.
- Men or women, aged 18 or over and capable of giving informed consent.
- Willing to consent to provide tissue and blood for translational research.
- Informed consent prior to any study specific procedures.
Exclusion Criteria - Registration (Stage 1):
- Evidence of small cell, large cell neuroendocrine or carcinoid histology.
- Have a serious or uncontrolled medical condition that could compromise the patients' ability to adhere to the protocol.
- Have a secondary malignancy (except adequately treated non-melanomatous skin cancer, or other cancer considered cured by surgical resection or radiation). Patients who have had another malignancy in the past but have been disease free for more than 5 years are eligible.
- Previous treatment with PARP inhibitors
- Uncontrolled gastrointestinal disorders such as active diverticulitis or colitis, or any major GI resection which could have an impact on patients' ability to absorb Olaparib.
- Myelodysplastic syndrome (MDS) or acute myeloid leukaemia (AML).
Inclusion Criteria - Randomisation (Stage 2):
- Confirmed diagnosis of NSCLC (either squamous or non-squamous). Stage IIIB or stage IV that is not amenable to curative therapy.
- ECOG performance status 0-1
- Evidence of radiological response to induction chemotherapy, from the pre-treatment to baseline. This can include mixed stable/response or evidence of tumour shrinkage that does not reach the criteria of partial response according to RECIST.
- Have had no prior systemic chemotherapy for advanced NSCLC. Previous adjuvant or neoadjuvant chemotherapy for non-advanced disease is acceptable. Previous palliative radiotherapy to non-target metastases is allowed provided no more than 25% of the bone marrow volume is irradiated. Irradiated sites cannot include the sites of measurable disease unless clear tumour progression has been documented in them since the end of radiation therapy. Patients who have had adjuvant therapy and then progressed after a year of completing adjuvant therapy are eligible. Patients who have received an oral inhibitor for molecularly stratified subgroups e.g. EGFR or ALK mutated lung cancer, are allowed. Immunotherapy e.g. with a PD1 or PDL1 targeted agent is allowed.
Adequate organ function, including the following:
- Adequate bone marrow reserve: White cell count ≥ 3.0 x 109/L, absolute neutrophil count (ANC) ≥ 1.5 x 109/L, platelets ≥ 100 x 109/L, haemoglobin ≥ 90g/L.
- Hepatic: total bilirubin ≤ 1.5 times the upper limit of normal (x ULN); alkaline phosphatase (ALP), aspartate aminotransferase (AST), or alanine aminotransferase (ALT) ≤ 2.5 x ULN. ALP, AST, and ALT ≤ 5 x ULN is acceptable if the liver has tumour involvement.
- Renal: calculated creatinine clearance (CrCl) ≥ 50mL/min using Cockcroft-Gault or Wright formula, serum creatinine ≤ 1.5 x institutional upper limit of normal (ULN).
- If blood count/morphology suggestive of MDS/AML, no features suggestive of MDS/AML on peripheral blood smear.
- Patients with reproductive potential (male or female), who are sexually active for the duration of the trial or the drug washout period, should be prepared to use two effective forms of contraception.
- Men or women, aged 18 or over.
- Willing to consent to provide tissue and blood for translational research.
- Patients must provide informed consent prior to any study specific procedures.
- There should be no more than 42 days between day 1 of the last cycle of induction chemotherapy and starting Olaparib/placebo.
Exclusion Criteria - Randomisation (Stage 2):
- Evidence of small cell, large cell neuroendocrine or carcinoid histology.
- Patients with radiological disease progression or stable disease after induction chemotherapy
- Have received treatment with an agent that has not received regulatory approval, within 30 days of study entry.
- Have had a blood transfusion within 28 days prior to commencing Olaparib or have a WBC <3 x 109/L
- Have received yellow fever vaccination in the 30 days prior to randomisation.
- Difficulty swallowing.
- Have central nervous system (CNS) metastases (unless the patient has completed successful local therapy for CNS metastases e.g. involving complete surgical removal or radical radiotherapy to a solitary CNS metastasis). A
- Concurrent administration of any other systemic antitumour therapy.
- Have a serious or uncontrolled medical condition that would compromise the patient's ability to adhere to the protocol.
- Diagnosis of a second malignancy (except adequately treated non-melanomatous skin cancer, or other cancer that is considered cured by surgical resection or radiation). Patient who had another malignancy in the past but have been disease free for more than 5 years are eligible.
- Previous treatment with PARP inhibitors.
- Uncontrolled gastrointestinal disorders such as active diverticulitis or colitis, or any major GI resection which could have an impact on patients' ability to absorb Olaparib.
- Myelodysplastic syndrome (MDS) or acute myeloid leukaemia (AML).
- Pregnant or breastfeeding.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Olaparib
3 100mg tablets to be administered twice a day with approximately 240ml of water.
|
Olaparib is a potent inhibitor of poly (ADP-ribose) polymerase enzyme (PARP), (molecular weight 434) that is being developed as a monotherapy as well as for combination with chemotherapy and other anti-cancer agents.
Olaparib can lead to tumour regression in patients with DNA repair deficient NSCLC.
Olaparib may also enhance the DNA damaging effects of chemotherapy.
Other Names:
|
Placebo Comparator: Placebo
3 100mg tablets to be administered twice a day with approximately 240ml of water.
|
3 100mg tablets to be administered twice a day with approximately 240ml of water
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival
Time Frame: 72 weeks
|
To establish the anti-tumour activity of Olaparib (measured by progression free survival),we will document the time from randomisation to any disease progression and/or death, defined according to strict RECIST (Response Evaluation Criteria in Solid Tumours) v1.1.
Lesions will be compared to baseline measurements to assess progression.
|
72 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety
Time Frame: 72 weeks
|
An Independent Data Monitoring Committee will convene and assess safety when 10 and 20 patients on each arm have completed trial treatment.
If the trial is deemed safe to continue then safety will be assessed again approximately every six months.
Toxicity data will be assessed along with serious adverse events.
|
72 weeks
|
Objective response rate
Time Frame: 72 weeks
|
This will be assessed based on radiological disease progression defined according to RECIST (Response Evaluation Criteria in Solid Tumours) v1.1.
|
72 weeks
|
Overall survival
Time Frame: 72 weeks
|
This will be calculated from the time of randomisation to date of death or date last known to be alive.
|
72 weeks
|
Change in tumour volume reduction
Time Frame: 27 weeks
|
Change in tumour volume reduction from randomisation to 6 months
|
27 weeks
|
Tolerability
Time Frame: 72 weeks
|
This will be assessed in terms of the number of treatment reductions, delays and withdrawals.
|
72 weeks
|
Feasibility
Time Frame: 72 weeks
|
Patients will complete a diary card every day to document compliance.
Feasibility of use will also be assessed in terms of number of treatment reductions, delays and withdrawals.
|
72 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Dean Fennell, Professor, University of Leicester
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Poly(ADP-ribose) Polymerase Inhibitors
- Olaparib
Other Study ID Numbers
- PIN
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-small Cell Lung Cancer
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
AIO-Studien-gGmbHBristol-Myers Squibb; Eli Lilly and Company; Merck Sharp & Dohme LLC; Pfizer; Gilead... and other collaboratorsRecruitingSmall-cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage I | Metastatic Non-small Cell Lung Cancer (NSCLC) | Non Small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer Stage IIGermany
-
University of California, San FranciscoAstraZenecaActive, not recruitingStage IIIA Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Cancer | Stage IB Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Cancer | Stage IIB Non-Small Cell Lung CancerUnited States
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)CompletedStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Healthy, no Evidence of Disease | Limited Stage Small Cell Lung... and other conditionsUnited States
-
Alexander ChiNot yet recruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Carcinoma | Non-small Cell Lung Cancer Stage IIChina
-
National Cancer Institute (NCI)Not yet recruitingStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerCanada
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States
-
Karen KellyBristol-Myers Squibb; National Cancer Institute (NCI); TransgeneCompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung CancerUnited States
-
Stanford UniversityAstraZenecaRecruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Lung Cancer Stage IIUnited States
-
Ohio State University Comprehensive Cancer CenterActive, not recruitingStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States
Clinical Trials on Olaparib
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingSmall Cell Lung Carcinoma | Small-cell Lung CancerUnited States
-
AstraZenecaMerck Sharp & Dohme LLC; Iqvia Pty LtdCompletedMalignant Solid TumorBelgium
-
Dana-Farber Cancer InstituteNovartis; AstraZenecaCompleted
-
AstraZenecaMerck Sharp & Dohme LLC; European Network of Gynaecological Oncological Trial... and other collaboratorsActive, not recruitingRelapsed Ovarian Cancer | Following Complete or Partial Response to Platinum Based Chemotherapy | Platinum Sensitive | BRCA MutatedKorea, Republic of, France, China, Italy, United States, Israel, United Kingdom, Canada, Japan, Germany, Brazil, Netherlands, Belgium, Poland, Australia, Russian Federation, Spain
-
Nordic Society of Gynaecological Oncology - Clinical...Hellenic Cooperative Oncology Group; European Network of Gynaecological Oncological... and other collaboratorsRecruiting
-
SandozCompleted
-
AstraZenecaEuropean Network of Gynaecological Oncological Trial Groups (ENGOT)CompletedEpithelial Ovarian CancerDenmark, France, Germany, Italy, Spain, Poland, Belgium, Canada, United Kingdom, Israel, Norway
-
Qilu Pharmaceutical Co., Ltd.Completed
-
AstraZenecaNo longer availablePSR Ovarian Cancer With a BRCA MutationJapan
-
AstraZenecaMerck Sharp & Dohme LLC; Myriad Genetic Laboratories, Inc.CompletedRecurrent Platinum Resistant Ovarian CancerUnited States